Login to Your Account

Chondrial sets up rare disease shop with in-licensed asset, series A

By Marie Powers
News Editor

Monday, February 6, 2017

Three-year-old Chondrial Therapeutics Inc. scored a series A financing of up to $22.6 million and licensed its first asset in a quest to build a pipeline of therapies to treat rare mitochondrial diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription